AUB ScholarWorks

How I treat adult T-cell leukemia-lymphoma

Show simple item record Bazarbachi A. Suarez F. Fields P. Hermine O.
dc.contributor.editor Aug-2011 2017-10-05T15:39:43Z 2017-10-05T15:39:43Z 2011
dc.identifier 10.1182/blood-2011-03-345702
dc.identifier.issn 00064971
dc.description.abstract Adult T-cell leukemia-lymphoma (ATL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I. ATL carries a bad prognosis because of intrinsic chemoresistance and severe immunosuppression. In acuteATL, Japanese trials demonstrated that although combinations of chemotherapy improved response rate, they failed to achieve a significant impact on survival. Patients with chronic and smoldering ATL have a better prognosis, but long-term survival is poor when these patients are managed with a watchful-waiting policy or with chemotherapy. Recently, a worldwide meta-analysis revealed that the combination of zidovudine and IFN-α is highly effective in the leukemic subtypes of ATL and should be considered as standard first-line therapy in that setting. This combination has changed the natural history of the disease through achievement of significantly improved long-term survival in patients with smoldering and chronic ATL as well as a subset of patients with acute ATL. ATL lymphoma patients still benefit from chemotherapy induction with concurrent or sequential antiretroviral therapy with zidovudine-IFN. To prevent relapse, clinical trials assessing consolidative targeted therapies such as arsenic-IFN combination or novel monoclonal antibodies are needed. Finally, allogeneic BM transplantation should be considered in suitable patients. © 2011 by The American Society of Hematology.
dc.format.extent Pages: (1736-1745)
dc.language English
dc.publisher WASHINGTON
dc.relation.ispartof Publication Name: Blood; Publication Year: 2011; Volume: 118; no. 7; Pages: (1736-1745);
dc.source Scopus
dc.title How I treat adult T-cell leukemia-lymphoma
dc.type Review
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, American University of Beirut, PO Box 113-6044, Beirut, Lebanon
dc.contributor.affiliation Suarez, F., CNRS 8147, Hôpital Necker, University of Paris Descartes, 149, Rue de Sèvres, 75743 Paris Cedex 15, France
dc.contributor.affiliation Fields, P., Department of Haematology, Guys and St. Thomas Hospital, Kings Health Partners, London, United Kingdom
dc.contributor.affiliation Hermine, O., CNRS 8147, Hôpital Necker, University of Paris Descartes, 149, Rue de Sèvres, 75743 Paris Cedex 15, France
dc.contributor.authorAddress Bazarbachi, A.; Department of Internal Medicine, American University of Beirut, PO Box 113-6044, Beirut, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorInitials Suarez, F
dc.contributor.authorInitials Fields, P
dc.contributor.authorInitials Hermine, O
dc.contributor.authorReprintAddress Bazarbachi, A (reprint author), Amer Univ Beirut, Dept Internal Med, POB 113-6044, Beirut, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Abbaszadegan MR, 2003, J CLIN MICROBIOL, V41, P2593, DOI 10.1128-JCM.41.6.2593-2595.2003; AMAGASAKI T, 1985, BLUT, V50, P209, DOI 10.1007-BF00320296; Arnulf B, 2004, LEUKEMIA, V18, P126, DOI 10.1038-sj.leu.2403176; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182-blood-2001-12-0372; Asquith B, 2000, PHILOS T ROY SOC B, V355, P1013; Azimi N, 1999, J IMMUNOL, V163, P4064; Banerjee P, 2007, J VIROL, V81, P1690, DOI 10.1128-JVI.01513-06; Bazarbachi A, 2010, J CLIN ONCOL, V28, P4177, DOI 10.1200-JCO.2010.28.0669; Bazarbachi A, 1999, BLOOD, V93, P278; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016-S0168-1702(01)00286-6; Bazarbachi A, 2004, CANCER RES, V64, P2039, DOI 10.1158-0008-5472.CAN-03-2390; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097-00042560-199600001-00028; Bellon M, 2006, INT J CANCER, V119, P2090, DOI 10.1002-ijc.22026; Besson C, 2002, LEUKEMIA LYMPHOMA, V43, P2275, DOI 10.1080-1042819021000039983; Bittencourt AL, 2007, AM J CLIN PATHOL, V128, P875, DOI 10.1309-2YGD1P0QCVCWBLDX; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186-1742-4690-5-76; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056-NEJM198308043090501; Callens C, 2008, LEUKEMIA, V22, P42, DOI 10.1038-sj.leu.2404958; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182-blood-2006-01-0067; DEARDEN C, 1991, BRIT J CANCER, V64, P903, DOI 10.1038-bjc.1991.423; El Hajj H, 2010, J EXP MED, V207, P2785, DOI 10.1084-jem.20101095; El-Sabban ME, 2002, BLOOD, V99, P3383, DOI 10.1182-blood.V99.9.3383; El-Sabban ME, 2000, BLOOD, V96, P2849; Fraedrich K, 2005, RETROVIROLOGY, V2, DOI 10.1186-1742-4690-2-54; FRANCHINI G, 2000, VIRAL DIS HEMATOLOGY, P409; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073-pnas.81.19.6207; FRANCHINI G, 1995, BLOOD, V86, P3619; Fukushima T, 2005, LEUKEMIA, V19, P829, DOI 10.1038-sj.leu.2403682; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038-sj.onc.1206468; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073-pnas.93.1.265; GESSAIN A, 1991, J VIROL, V65, P1628; GESSAIN A, 1996, HUMAN T CELL LYMPHOT, P33; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056-NEJM199506293322603; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038-sj.onc.1208978; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038-nm1389; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056-NEJM199506293322604; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038-sj.thj.6200374; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038-sj.thj.6200195; Hermine O, 1998, BIODRUGS, V10, P447, DOI 10.2165-00063030-199810060-00003; Hishizawa M, 2010, BLOOD, V116, P1369, DOI 10.1182-blood-2009-10-247510; HODSON A, 2010, ADDITION ANTIVIRAL T; HODSON A, 2010, 52 ANN M AM SOC HEM; Jin DY, 1998, CELL, V93, P81, DOI 10.1016-S0092-8674(00)81148-4; Kami M, 2003, BRIT J HAEMATOL, V120, P304, DOI 10.1046-j.1365-2141.2003.04054.x; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002-rmv.1980030304; Kchour G, 2007, LEUKEMIA LYMPHOMA, V48, P330, DOI 10.1080-10428190601071717; Kchour G, 2009, BLOOD, V113, P6528, DOI 10.1182-blood-2009-03-211821; Kfoury Y, 2005, CELL DEATH DIFFER, V12, P871, DOI 10.1038-sj.cdd.4401624; Kfoury Y, 2008, ONCOGENE, V27, P1665, DOI 10.1038-sj.onc.1210804; Kfoury Y, 2011, BLOOD, V117, P190, DOI 10.1182-blood-2010-05-285742; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002-1097-0142(19870315)59:61187::AID-CNCR28205906263.0.CO;2-8; KUWAZURU Y, 1990, BLOOD, V76, P2065; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128-MCB.25.23.10391-10406.2005; Lau A, 1998, BLOOD, V91, P2467; LENNERT K, 1985, INT J CANCER, V35, P65, DOI 10.1002-ijc.2910350111; LorandMetze I, 1996, LEUKEMIA LYMPHOMA, V22, P523, DOI 10.3109-10428199609054793; Mahieux R, 2001, BLOOD, V98, P3762, DOI 10.1182-blood.V98.13.3762; MARUYAMA K, 1990, CANCER RES, V50, pS5697; Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186-1742-4690-6-71; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038-nrc2111; Matutes E, 2001, BRIT J HAEMATOL, V113, P779, DOI 10.1046-j.1365-2141.2001.02794.x; Mone A, 2005, BLOOD, V106, P3380, DOI 10.1182-blood-2005-01-0335; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128-JVI.75.2.1083-1089.2001; Moura IC, 2004, BLOOD, V103, P1838, DOI 10.1182-blood-2003-07-2440; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182-blood-2002-09-2986; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182-blood-2005-09-3572; Ohshima K, 1998, BRIT J HAEMATOL, V101, P703, DOI 10.1046-j.1365-2141.1998.00761.x; Okamura J, 2005, BLOOD, V105, P4143, DOI 10.1182-blood-2004-11-4193; PAUN L, 1994, EUR J HAEMATOL, V52, P117; Phillips AA, 2009, LEUKEMIA LYMPHOMA, V50, P1039, DOI 10.1080-10428190902887571; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182-blood.V98.4.1200; Ramos JC, 2007, BLOOD, V109, P3060, DOI 10.1182-blood-2006-07-036368; Ratner L, 2009, PLOS ONE, V4, DOI 10.1371-journal.pone.0004420; Ravandi F, 2006, LEUKEMIA RES, V30, P103, DOI 10.1016-j.leukres.2005.05.008; RIO B, 1990, PRESSE MED, V19, P746; SAKASHITA A, 1992, BLOOD, V79, P477; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073-pnas.0507631103; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111-j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1992, ADV ADULT T CELL LEU, V39, P43; SHIRONO K, 1994, LEUKEMIA, V8, P1834; Swerdlow SH, 2008, WHO CLASSIFICATION T; Tabakin-Fix Y, 2006, CARCINOGENESIS, V27, P673, DOI 10.1093-carcin-bgi274; Taguchi H, 1996, J ACQ IMMUN DEF SYND, V12, P182; Takasaki Y, 2010, BLOOD, V115, P4337, DOI 10.1182-blood-2009-09-242347; Takatsuki F, 1990, RETROVIRUS BIOL HUMA, P147; TAKEMOTO S, 1994, BLOOD, V84, P3080; TANABE K, 1991, CANCER RES, V51, P4903; Taylor JM, 2008, APOPTOSIS, V13, P733, DOI 10.1007-s10495-008-0208-7; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073-pnas.87.13.5218; TOBINAI K, 1992, JPN J CLIN ONCOL, V22, P164; Tobinai K, 2009, ONCOLOGY-NY, V23, P1250; TSUDA H, 1994, BRIT J CANCER, V70, P771, DOI 10.1038-bjc.1994.394; Tsukasaki K, 2003, INT J HEMATOL, V77, P164, DOI 10.1007-BF02983215; Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200-JCO.2008.18.2428; Tsukasaki K, 1997, BLOOD, V89, P948; Tsukasaki K, 2007, J CLIN ONCOL, V25, P5458, DOI 10.1200-JCO.2007.11.9958; Tsukasaki K, 1999, BONE MARROW TRANSPL, V23, P87, DOI 10.1038-sj.bmt.1701533; UCHIYAMA T, 1977, BLOOD, V50, P481; UTSUNOMIYA A, 1988, CANCER, V61, P824, DOI 10.1002-1097-0142(19880215)61:4824::AID-CNCR28206104303.0.CO;2-6; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038-sj.bmt.1702731; Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016-S1473-3099(07)70081-6; WALDMANN TA, 1995, BLOOD, V86, P4063; WALDMANN TA, 1985, CANCER RES, V45, P4559; WALDMANN TA, 1993, BLOOD, V82, P1701; WATTEL E, 1995, J VIROL, V69, P2863; White JD, 2001, LEUKEMIA LYMPHOMA, V40, P287, DOI 10.3109-10428190109057927; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046-j.1365-2141.2001.02737.x; Yamamoto K, 2010, J CLIN ONCOL, V28, P1591, DOI 10.1200-JCO.2009.25.3575; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146-annurev.immunol.19.1.475; Zhang Z, 2003, BLOOD, V102, P284, DOI 10.1182-blood-2002-11-3601
dc.description.citedCount 25
dc.description.citedTotWOSCount 26
dc.description.citedWOSCount 23
dc.format.extentCount 10
dc.identifier.coden BLOOA
dc.identifier.pubmedID 21673346
dc.identifier.scopusID 80051899384
dc.publisher.address 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
dc.relation.ispartOfISOAbbr Blood
dc.relation.ispartOfIssue 7
dc.relation.ispartofPubTitle Blood
dc.relation.ispartofPubTitleAbbr Blood
dc.relation.ispartOfVolume 118
dc.source.ID WOS:000294011500011
dc.type.publication Journal
dc.subject.otherChemCAS alemtuzumab, 216503-57-0
dc.subject.otherChemCAS arsenic trioxide, 1303-24-8, 1327-53-3, 13464-58-9, 15502-74-6
dc.subject.otherChemCAS carboplatin, 41575-94-4
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS etoposide, 33419-42-0
dc.subject.otherChemCAS lamivudine, 134678-17-4, 134680-32-3
dc.subject.otherChemCAS mogamulizumab, 1159266-37-1
dc.subject.otherChemCAS prednisolone, 50-24-8
dc.subject.otherChemCAS prednisone, 53-03-2
dc.subject.otherChemCAS ranimustine, 58994-96-0
dc.subject.otherChemCAS siplizumab, 288392-69-8
dc.subject.otherChemCAS sobuzoxane, 98631-95-9
dc.subject.otherChemCAS vincristine, 57-22-7
dc.subject.otherChemCAS vincristine sulfate, 2068-78-2
dc.subject.otherChemCAS vindesine, 53643-48-4
dc.subject.otherChemCAS zalcitabine, 7481-89-2
dc.subject.otherChemCAS zidovudine, 30516-87-1
dc.subject.otherChemCAS Anti-Retroviral Agents
dc.subject.otherChemCAS Antibodies, Monoclonal
dc.subject.otherChemCAS Antineoplastic Agents
dc.subject.otherChemCAS Arsenicals
dc.subject.otherChemCAS Oxides
dc.subject.otherChemCAS arsenic trioxide, 1327-53-3
dc.subject.otherIndex alemtuzumab
dc.subject.otherIndex alpha interferon
dc.subject.otherIndex arsenic trioxide
dc.subject.otherIndex carboplatin
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex deoxycoformycine
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex etoposide
dc.subject.otherIndex interferon
dc.subject.otherIndex lamivudine
dc.subject.otherIndex mogamulizumab
dc.subject.otherIndex nucleoside analog
dc.subject.otherIndex prednisolone
dc.subject.otherIndex prednisone
dc.subject.otherIndex ranimustine
dc.subject.otherIndex siplizumab
dc.subject.otherIndex sobuzoxane
dc.subject.otherIndex unclassified drug
dc.subject.otherIndex vincristine
dc.subject.otherIndex vincristine sulfate
dc.subject.otherIndex vindesine
dc.subject.otherIndex zalcitabine
dc.subject.otherIndex zidovudine
dc.subject.otherIndex antiviral therapy
dc.subject.otherIndex cancer combination chemotherapy
dc.subject.otherIndex cancer relapse
dc.subject.otherIndex cancer staging
dc.subject.otherIndex cancer survival
dc.subject.otherIndex clinical trial (topic)
dc.subject.otherIndex comparative study
dc.subject.otherIndex human
dc.subject.otherIndex Human T cell leukemia virus infection
dc.subject.otherIndex Japanese
dc.subject.otherIndex meta analysis
dc.subject.otherIndex nonhuman
dc.subject.otherIndex pathogenesis
dc.subject.otherIndex priority journal
dc.subject.otherIndex prognosis
dc.subject.otherIndex review
dc.subject.otherIndex survival time
dc.subject.otherIndex T cell leukemia
dc.subject.otherIndex treatment response
dc.subject.otherIndex tumor cell
dc.subject.otherIndex Anti-Retroviral Agents
dc.subject.otherIndex Antibodies, Monoclonal
dc.subject.otherIndex Antineoplastic Agents
dc.subject.otherIndex Arsenicals
dc.subject.otherIndex Hematopoietic Stem Cell Transplantation
dc.subject.otherIndex HTLV-I Infections
dc.subject.otherIndex Human T-lymphotropic virus 1
dc.subject.otherIndex Humans
dc.subject.otherIndex Leukemia-Lymphoma, Adult T-Cell
dc.subject.otherIndex Oxides
dc.subject.otherKeywordPlus VIRUS TYPE-I
dc.subject.otherKeywordPlus KAPPA-B ACTIVATION
dc.subject.otherKeywordPlus LEUKEMIA-LYMPHOMA
dc.subject.otherKeywordPlus HTLV-I
dc.subject.otherKeywordPlus INTERFERON-ALPHA
dc.subject.otherKeywordPlus MONOCLONAL-ANTIBODY
dc.subject.otherKeywordPlus ARSENIC TRIOXIDE
dc.subject.otherKeywordPlus TRANSFORMED-CELLS
dc.subject.otherKeywordPlus COMBINATION CHEMOTHERAPY
dc.subject.otherKeywordPlus MOLECULAR-MECHANISMS
dc.subject.otherWOS Hematology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account